Hélène Peyro-Saint-Paul
Chief Tech/Sci/R&D Officer en QIAGEN MARSEILLE .
Cargos activos de Hélène Peyro-Saint-Paul
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| QIAGEN MARSEILLE | Chief Tech/Sci/R&D Officer | 26/01/2009 | - |
Historial de carrera de Hélène Peyro-Saint-Paul
Antiguos cargos conocidos de Hélène Peyro-Saint-Paul.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Chief Tech/Sci/R&D Officer | - | - |
Formación de Hélène Peyro-Saint-Paul.
| Université Fédérale Toulouse Midi-Pyrénées | Doctorate Degree |
| ESSEC Business School | Masters Business Admin |
Estadísticas
Internacional
| Francia | 6 |
Operativa
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sectorial
| Consumer Services | 4 |
| Commercial Services | 2 |
| Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 3 |
|---|---|
| Université Pierre et Marie Curie | Consumer Services |
QIAGEN Marseille SA
 QIAGEN Marseille SA Miscellaneous Commercial ServicesCommercial Services QIAGEN Marseille SA is a molecular diagnosis company, which focuses on the development and marketing of diagnostic tests in the field of oncology. Its products are used for diagnosis, prognosis and monitoring of patients with leukemia. The company was founded by Vincent Fert, Stéphane Debono, and Fabienne Hermitte on September 23, 1999 and is headquartered in Marseille, France. | Commercial Services |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Health Technology |
